Literature DB >> 7128666

Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers.

M Theisohn, G Heimann.   

Abstract

Oxcarbazepine (oxcarb) 600 and 900 mg (2360 and 3540 mumol) was taken by 3 volunteers (2 female, 1 male; 45-67 kg; age 22-34 years) after an overnight fast. Blood, saliva and urine were collected for the next 72 h for assay of oxcarb, 10,11-dihydro-10-hydroxy-carbamazepine (OHcarb), and 10,11-dihydro-trans-10,11-dihydroxy-carbamazepine (diol). Oxcarb reached a maximum level of about 1 microgram/ml (3.93 mumol/l) within 1 h and dropped below the detection limit (0.1 microgram/ml = 0.39 mumol/l) within 3 h. The active metabolite OHcarb appeared in the blood before oxcarb and reached the higher maximum level of 7.4 microgram/ml (29 mumol/l) after 7 h. Thereafter serum levels decreased with a t1/2 of about 25 h, and after 40 h with a t1/2 of 9 h, the latter agreeing with the renal excretory t1/2 calculated from the urine data (10 h). The ratio of OHcarb concentration in saliva to that in plasma varied considerably (0.3-1.7; median 1; r greater than 0.9), whereas that of blood to plasma was 1.25 with only small variation (r greater than 0.98); OHcarb concentrations in erythrocytes were 50% higher than in plasma. Diol was detected in blood (maximum level 0.5 microgram/ml = 1.84 mumol/l) in 2 volunteers. 45% of the dose could be recovered in urine (Oxcarb 5%, OH-carb 36%, Diol 4%). Whereas Oxcarb was completely conjugated, only 25% of OHcarb was conjugated and diol was unconjugated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128666     DOI: 10.1007/bf00609629

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers.

Authors:  H M von Hattingberg; D Brockmeier; G Kreuter
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

2.  [Pharmacokinetic methods for the evaluation of intestinal absorption].

Authors:  W Kübler
Journal:  Z Kinderheilkd       Date:  1970

3.  [Antiepileptic long-term therapy in the adult age].

Authors:  C Passarge
Journal:  Dtsch Med Wochenschr       Date:  1978-10-13       Impact factor: 0.628

4.  Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy.

Authors:  M Eichelbaum; K W Köthe; F Hoffman; G E von Unruh
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

  4 in total
  21 in total

1.  Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine.

Authors:  Ali Sigaroudi; Gerd A Kullak-Ublick; Stefan Weiler
Journal:  Eur J Clin Pharmacol       Date:  2015-12-03       Impact factor: 2.953

2.  Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia.

Authors:  P N Patsalos; A A Elyas; J M Zakrzewska
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

4.  First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.

Authors:  R G Dickinson; W D Hooper; P R Dunstan; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

6.  Use of saliva for monitoring oxcarbazepine therapy in epileptic patients.

Authors:  N A Klitgaard; O Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 8.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

9.  Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.

Authors:  J M Zakrzewska; P N Patsalos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

Review 10.  Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.

Authors:  S M Grant; D Faulds
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.